The ventrogluteal site is the area on the side of the hip overlying the gluteus medius and gluteus minimus muscles, and most current nursing evidence recommends it as the preferred location for intramuscular injections in adults. First proposed by the Swiss anatomist Von Hochstetter in 1954 as a way to avoid sciatic nerve injuries, the site has since accumulated decades of research showing it causes less pain, less bleeding, and fewer complications than the traditional upper-outer buttock injection most people are familiar with. Despite that evidence, it remains underused in clinical practice for reasons that have more to do with habit and training gaps than anatomy.
Where Exactly the Ventrogluteal Site Is
The ventrogluteal site sits on the lateral hip, roughly between the bony prominence you can feel at the top of your hip (the iliac crest) and the greater trochanter, the knob of bone at the top of your thigh. The muscles underneath are the gluteus medius and gluteus minimus, which are the deep muscles responsible for stabilizing your pelvis when you walk. This is a different area from the dorsogluteal site, the classic “upper outer quadrant” of the buttock that targets the gluteus maximus, the large surface muscle you sit on.
The ventrogluteal region has several anatomical advantages. It is relatively far from the sciatic nerve, which runs through the lower buttock and is the nerve most at risk during dorsogluteal injections. It also has fewer large blood vessels, with the exception of some branches of the superior gluteal artery and vein. A cadaver study found that the distance from the ventrogluteal injection point to the superior gluteal artery averaged about 14 mm, and the distance to the superior gluteal nerve averaged about 12 mm, with considerable variation between individuals.1PubMed. The evaluation of dorsogluteal and ventrogluteal injection sites: a cadaver study The subcutaneous fat layer at the ventrogluteal site tends to be thinner than at the dorsogluteal site, which makes it easier for the needle to reach muscle tissue and reduces the chance of accidentally depositing medication into fat.
How to Locate the Site
Two main landmarking methods are used to find the ventrogluteal site: the V method and the G (geometric) method. In the V method, the clinician places the heel of their hand on the greater trochanter, points the index finger toward the anterior superior iliac spine (the bony point at the front of the hip), and spreads the middle finger toward the iliac crest, forming a V shape. The injection goes into the center of that V. In the G method, the clinician identifies specific bony landmarks and uses a geometric calculation to find the midpoint of the gluteus medius.
Research comparing the two methods consistently favors the G method. One ultrasound-verified study found that the G method produced a successful intramuscular injection about 75% of the time compared with 57% for the V method, and that the G method site had thicker underlying muscle.2PubMed. Comparison of the G and V methods for ventrogluteal site identification: Muscle and subcutaneous fat thicknesses and considerations for successful intramuscular injection The G method also carries less risk of hitting bone, because it targets a meatier portion of the gluteus medius. A separate cross-sectional study examining both methods under ultrasound concluded that when using the ventrogluteal site, the geometric method should be the preferred landmarking approach.3PubMed. The reliability of site determination methods in ventrogluteal area injection: a cross-sectional study
An ultrasound study of tissue layers at both ventrogluteal landmarks and the dorsogluteal site confirmed that the G-method ventrogluteal site had a thicker gluteus medius than the V-method site, while the dorsogluteal site had thicker subcutaneous fat and a thicker gluteus maximus. The gluteus medius was the thickest muscle at every injection site, making it the primary target tissue for ventrogluteal injections.4PubMed. Effects of thickness of muscle and subcutaneous fat on efficacy of gluteal intramuscular injection sites
Less Pain, Bleeding, and Bruising
The most compelling practical argument for the ventrogluteal site is that it simply hurts less. A systematic review and meta-analysis pooling nine studies found that ventrogluteal injections were associated with meaningfully lower pain scores compared with dorsogluteal injections. The same analysis found less bleeding across four studies and less hematoma formation at both 48 and 72 hours after injection.5PubMed Central. Adverse effects of dorsogluteal intramuscular injection versus ventrogluteal intramuscular injection: A systematic review and meta-analysis Individual trials back this up. One Turkish study that gave each patient injections at both sites reported average pain scores of about 2.2 on a 10-point scale for the ventrogluteal site versus about 3.7 for the dorsogluteal, with bleeding and bruising rates roughly halved at the ventrogluteal location.6Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi. Ventrogluteal ve Dorsogluteal Bölgeye Uygulanan İntramüsküler Enjeksiyonların Kanama, Ağrı ve Hematom Açısından Karşılaştırılması
The lower complication rates make intuitive sense given the anatomy. The ventrogluteal region has less subcutaneous fat, fewer large vessels, and the target muscles sit away from major nerves. Dorsogluteal injections carry a small but real risk of sciatic nerve injury, which can cause shooting pain down the leg, foot drop, or lasting nerve damage. That risk is essentially absent at the ventrogluteal site, which was Von Hochstetter’s original motivation for proposing it.
Choosing the Right Needle Length
Even at a site with thinner fat, needle length still matters. If the needle is too short, the medication ends up in subcutaneous tissue instead of muscle, which can slow absorption and increase local irritation. If the needle is too long, it can hit bone. The right length depends heavily on the patient’s body size and sex.
One study measuring the depth from skin to muscle at the ventrogluteal site found that the needed needle penetration depth ranged from about 20 to 48 mm in thin women, 18 to 53 mm in women of normal weight, 29 to 62 mm in overweight women, and 26 to 88 mm in obese women. In men, the ranges were 23 to 37 mm in thin men, 18 to 41 mm in normal-weight men, 25 to 50 mm in overweight men, and 17 to 82 mm in obese men. The ranges were statistically different by both BMI category and sex.7Journal of Istanbul Faculty of Medicine. Needle Penetration Depth According to Gender and Body Mass Index in Ventrogluteal Intramuscular Injections in Adults The wide spread in obese patients is striking and highlights why a one-size-fits-all needle length does not work.
A study specifically examining how well BMI predicts subcutaneous fat thickness at the ventrogluteal site found a strong correlation (about 0.82 in women and 0.81 in men). The findings suggest that the standard 1.5-inch (3.75 cm) needle, which is still the most commonly used length for adult intramuscular injections, fails to reach muscle in roughly 71% of women with a BMI above 30 and about 60% of men with a BMI above 35.8American Journal of Therapeutics. Body Mass Index: A Reliable Predictor of Subcutaneous Fat Thickness and Needle Length for Ventral Gluteal Intramuscular Injections For patients in higher BMI ranges, clinicians may need needles of 2 inches or longer, and ideally should assess the area by palpation or ultrasound before injecting.
The Ventrogluteal Site in Children
For decades, the anterolateral thigh (vastus lateralis) has been the go-to injection site in infants and young children, because the gluteal muscles were thought to be insufficiently developed until a child had been walking for a year or more. More recent research challenges that assumption. An ultrasound study found that the ventrogluteal muscle was adequately developed even in infants between 1 and 12 months of age, and that in children aged 12 to 36 months, the ventrogluteal muscle was actually thicker than the anterolateral thigh.9PubMed. Is the ventrogluteal site suitable for intramuscular injections in children under the age of three?
A separate study measuring the ventrogluteal area in 642 children aged 2 to 18 months, with ultrasound verification in a subset of 57, confirmed that the site was clearly defined and suitable for intramuscular injection even in this young age group.10PubMed. Ventrogluteal area–a suitable site for intramuscular vaccination of infants and toddlers When the site is used in children, it appears to hurt less. A randomized controlled trial comparing ventrogluteal and vastus lateralis injections in children found that children in the ventrogluteal group had significantly lower pain scores immediately after injection on both visual and facial pain scales.11PubMed Central. Comparison of pain levels developed during intramuscular injections to laterofemoral and ventrogluteal regions in children: a randomized controlled study
A systematic review looking at ventrogluteal injection in children across multiple age groups concluded that the site carries less risk of nerve injury and fewer local and systemic side effects. The review did note that more research is still needed to establish broader safety guidelines, particularly for neonates.12Türk Hemşireler Derneği Dergisi. Preference Of the Ventrogluteal Region in Intramuscular Injection in Children: Systematic Review
Why It Works Better in Older Adults
Aging brings muscle loss, and one concern clinicians sometimes raise is whether the ventrogluteal site remains viable in elderly patients. A study examining both injection sites in older adults found that the ventrogluteal site had a mean muscle thickness of about 40 mm, compared with roughly 26 mm at the dorsogluteal site. Subcutaneous fat was actually thinner at the ventrogluteal site (about 20 mm versus 23 mm at the dorsogluteal). Both sites met the published thresholds for safe intramuscular injection, but the ventrogluteal site was more advantageous because of its thicker muscle and thinner fat layer.13PubMed Central. Examining the Safety of Dorsogluteal and Ventrogluteal Sites for Intramuscular Injection in Older Adults
This finding matters because the gluteus maximus, which is the target at the dorsogluteal site, tends to atrophy more with age and inactivity than the gluteus medius. In patients who are bedridden or have limited mobility, the dorsogluteal muscle may be too wasted to reliably absorb an intramuscular injection, while the ventrogluteal muscles often retain enough mass to serve as a viable target.
How Injection Site Affects Drug Absorption
Until recently, it was assumed that the specific gluteal site used for an intramuscular injection did not meaningfully affect how a drug was absorbed. A pharmacokinetic study of long-acting cabotegravir and rilpivirine, two antiretroviral drugs given as monthly or bimonthly injections, found otherwise. Ventrogluteal delivery produced higher one-month post-dose drug concentrations for both medications compared with dorsogluteal delivery. Cabotegravir levels were about 1,280 ng/mL versus 834 ng/mL, and rilpivirine levels were about 148 ng/mL versus 126 ng/mL.
At trough (the lowest point before the next dose), cabotegravir concentrations were actually lower with ventrogluteal injections, and a slightly higher proportion of samples fell below the target threshold for viral suppression in the ventrogluteal group (about 7% versus 1.5%). However, ventrogluteal administration produced lower variability in drug concentrations both within and between patients, meaning more predictable and consistent drug levels overall. The study’s authors concluded that ventrogluteal administration supports more consistent pharmacokinetics and better tolerability.14PubMed. Impact of Gluteal Injection Site on Pharmacokinetics and Tolerability of Antiretroviral Therapy with Long-Acting Cabotegravir and Rilpivirine
The mechanism likely involves differences in blood supply and fat content between the two sites. The dorsogluteal site’s thicker fat layer can act as an unintended depot, trapping medication in adipose tissue and releasing it erratically. The ventrogluteal site’s thinner fat and richer muscle blood supply allow more predictable uptake into the bloodstream. For medications where consistent blood levels matter, like antiretrovirals or long-acting antipsychotics, this is a clinically meaningful distinction.
Why Most Nurses Still Reach for the Dorsogluteal Site
If the evidence so strongly favors the ventrogluteal site, it is fair to wonder why the traditional upper buttock is still so widely used. The answer is mostly institutional inertia and education gaps. A cross-sectional survey of nursing staff found that the most common reasons for avoiding the ventrogluteal site were not being accustomed to it (about 31%), general unfamiliarity (27%), lack of adequate knowledge about the technique (about 20%), fear of harming the patient (about 9%), and not knowing how to locate the site (about 10%).15AUST J ADV NURS. The assessment of knowledge and practical skills of intramuscular injection administration among nursing staff: a cross-sectional study
Separate research found that only about a third of nurses frequently used the dorsogluteal site (suggesting the rest alternated or used other sites like the deltoid or thigh), and that training interventions made a substantial difference. Nurses who received targeted education about the ventrogluteal site showed large jumps in knowledge scores and were more willing to adopt the technique afterward.16PubMed Central. Creating a change in the use of ventrogluteal site for intramuscular injection The barrier is not skepticism about the evidence; it is that many nurses were trained on the dorsogluteal site, have performed thousands of injections there, and feel confident in a technique they know. Switching to an unfamiliar landmark on an unfamiliar part of the body feels risky even when the data say it is safer.
A mixed-methods study testing a mobile-assisted training program found that nurses who used the app had significantly higher scores on ventrogluteal injection skills after training and reported feeling less anxious about using the site. Participants said the intervention reinforced their existing knowledge and, crucially, gave them the confidence to actually try the technique on real patients.17PubMed Central. The effect of Mobile-Assisted training and counseling on nurses’ ventrogluteal injections application of nursing: A mixed method study
What to Know If You Are Getting an Injection
If you are a patient and someone is about to give you an intramuscular injection in the buttock, you can ask whether they are using the ventrogluteal site. The injection goes into the side of your hip rather than the upper-outer quadrant of the buttock cheek. You will typically be asked to lie on your side with the top leg slightly bent, or to stand and shift your weight to the opposite foot. The slight flexion helps relax the gluteus medius and makes it easier for the provider to identify the landmarks.
Do not be alarmed if the injection feels unfamiliar in location. Many patients expect a gluteal injection to go in the fleshy part of the buttock they sit on, and the ventrogluteal site feels surprisingly lateral, almost on the hip bone. That unfamiliarity is the point: the injection avoids the sciatic nerve corridor entirely.
If you have a higher BMI, it is reasonable to mention that to the provider and ask whether they have chosen an appropriate needle length. The research is clear that a standard 1.5-inch needle is insufficient for many overweight and obese patients at any gluteal site, and providers who are aware of this can select a longer needle or use palpation to gauge tissue depth before proceeding.18Medical Research Archives. Intramuscular Injection Guideline Revisions are Needed Based on Body Mass Index, Needle Length, Sex, and Skin to Muscle Depth A medication that ends up in fat instead of muscle does not absorb properly and can cause a painful lump at the injection site that lingers for days.
When the Dorsogluteal Site Might Still Be Used
For all its advantages, the ventrogluteal site is not always practical. Patients with hip replacements or hardware on the injection side, severe hip contractures, or wounds or skin conditions over the lateral hip may need an alternate site. Some very thin or cachectic patients may have so little tissue at the ventrogluteal site that the risk of hitting bone outweighs the benefits, particularly if the clinician cannot verify depth by palpation or ultrasound. In these cases the dorsogluteal, deltoid, or vastus lateralis sites remain valid alternatives.
Certain high-volume medications, such as large-volume oil-based injections (some testosterone formulations call for 3 mL or more), are traditionally given in the gluteus maximus because of its sheer size. Whether the smaller-targeted gluteus medius can comfortably absorb that volume in a single injection is still a matter of clinical judgment rather than settled research. Most guidelines recommend keeping ventrogluteal injection volumes to 3 mL or less in adults, though the gluteus medius can often tolerate that amount without difficulty.
The dorsogluteal site also remains the default in many emergency and field settings simply because it requires less precise landmarking under pressure. In a busy emergency department or a mass vaccination campaign, the speed and simplicity of the upper-outer-quadrant injection can outweigh the marginal safety advantage of the ventrogluteal approach, especially when a trained provider is confident in their dorsogluteal technique. The evidence favors the ventrogluteal site when conditions allow careful landmarking, but clinical reality sometimes dictates otherwise.